L

Lionco Pharmaceutical Group Co Ltd
SSE:603669

Watchlist Manager
Lionco Pharmaceutical Group Co Ltd
SSE:603669
Watchlist
Price: 4.67 CNY -0.85% Market Closed
Market Cap: 3.4B CNY

Wall Street
Price Targets

Price Targets Summary
Lionco Pharmaceutical Group Co Ltd

There are no price targets for Lionco Pharmaceutical Group Co Ltd.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
Lionco Pharmaceutical Group Co Ltd Competitors:
Price Targets
PHAT
Phathom Pharmaceuticals Inc
58% Upside
WEED
Canopy Growth Corp
57% Upside
MARI
Marinomed Biotech AG
172% Upside
4568
Daiichi Sankyo Co Ltd
70% Upside
ALDVI
Advicenne SA
125% Upside
688176
Jiangsu Yahong Meditech Co Ltd
3% Downside
INVA
Innoviva Inc
59% Upside
086450
Dongkook Pharmaceutical Co Ltd
38% Upside

Revenue
Forecast

Revenue Estimate
Lionco Pharmaceutical Group Co Ltd

For the last 11 years the compound annual growth rate for Lionco Pharmaceutical Group Co Ltd's revenue is -2%. The projected CAGR for the next 3 years is 39%.

-2%
Past Growth
39%
Estimated Growth
Estimates Accuracy
-20%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Lionco Pharmaceutical Group Co Ltd

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Net Income
Forecast

Net Income Estimate
Lionco Pharmaceutical Group Co Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-26%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is Lionco Pharmaceutical Group Co Ltd's stock price target?
Not Available

Lionco Pharmaceutical Group Co Ltd doesn't have any price targets made by Wall Street professionals.

What is Lionco Pharmaceutical Group Co Ltd's Revenue forecast?
Projected CAGR
39%

For the last 11 years the compound annual growth rate for Lionco Pharmaceutical Group Co Ltd's revenue is -2%. The projected CAGR for the next 3 years is 39%.

Back to Top